June 26, 2025

Medical Groups Unite on Vaccine Policy

Major medical associations jointly reaffirm commitment to respiratory virus vaccines amid federal immunization review process changes.

Conexiant

June 23, 2025

Older Adults Lead Vaccine Comeback

Older Americans are embracing vaccines—backed by new research confirming enhanced safety, disease prevention, and even a potential link to reduced dementia risk.

KFF Health News

June 17, 2025

FDA-Approved Sweetener Found in Vapes

New laboratory analysis found widespread use of neotame, a potent artificial sweetener, in most disposable e-cigarettes sold in the United States, including nicotine-free and nicotine-analogue products.

Conexiant

June 16, 2025

Cytisinicline Shows Efficacy In Smoking Cessation Trial 

A phase 3 randomized clinical trial found that cytisinicline, a partial agonist at α4β2 nicotinic acetylcholine receptors, improved smoking cessation rates compared with placebo, with higher abstinence rates and reduced craving over 24 weeks.

Conexiant

June 13, 2025

RSV Vaccine Approved for Younger Adults

The FDA has approved Moderna’s mRESVIA vaccine for adults aged 18 to 59 who are at increased risk for RSV, expanding its indication beyond older adults.

Conexiant

June 06, 2025

FDA Monthly Round-up: Key May Updates

May’s FDA approvals include the first at-home HPV test, a blood-based Alzheimer’s diagnostic, biosimilars, AI-enabled imaging tools, and novel therapies across cardiology, pulmonology, neurology, gastroenterology, and more.

Conexiant

June 04, 2025

Chemo Killed Her. A Test Might've Saved Her.

A fatal enzyme deficiency turned a common chemo drug toxic. With testing available—but rarely used—are clinicians missing a lifesaving step?

KFF Health News

June 03, 2025

FDA Grants Breakthrough Status to Shield Test

The methylation-based blood assay is designed for screening multiple cancer types.

Conexiant

June 02, 2025

New COVID Vaccine Approved for High-Risk Groups

After showing higher efficacy and a comparable safety profile to Spikevax, the FDA has approved Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk patients.

Conexiant